BRAF inhibition protects against hearing loss in mice
Abstract
Dabrafenib, an FDA-approved oral anticancer drug, prevents cisplatin- and noise-induced hearing loss in animal models.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 04, 2020
- Source ID
- 10.1126/sciadv.abd0561
Entities
People
- David Z Z He
- Duane Currier
- Emma A. Malloy
- Eva M Holland
- Huizhan Liu
- Jaeki Min
- Jian Zuo
- Lauryn E. Caster
- Marisa Zallocchi
- Matthew A Ingersoll
- Tal Teitz
- Taosheng Chen
- Zhenhang Xu
Organizations
- American Hearing Research Foundation
- Central South University
- Creighton University
- St. Jude Children's Research Hospital